Paternal, Maternal Depression May Up Asthma Risk for Baby

This article originally appeared here.
Share this content:
Paternal, Maternal Depression May Up Asthma Risk for Baby
Paternal, Maternal Depression May Up Asthma Risk for Baby

MONDAY, March 9, 2015 (HealthDay News) -- A child may face an increased risk of asthma if the child's mother or father experienced depression during the pregnancy or if the mother took an older antidepressant to treat her condition, new research suggests. The study findings were published online March 9 in Pediatrics.

Xiaoqin Liu, M.D., an epidemiologist at Aarhus University in Denmark, and colleagues analyzed the medical records of 733,685 Danish children born between 1996 and 2007. Of the children's mothers, 21,371 either had a diagnosis of depression or received a prescription for antidepressants while pregnant.

Children born to mothers who had depression were 25 percent more likely to develop childhood asthma. Among the 8,895 children whose mothers were prescribed antidepressants during pregnancy, the children of those women who received older antidepressants, mostly tricyclic antidepressants, had a 26 percent increased risk of asthma. The researchers also found that depression in fathers slightly increased children's risk of asthma, which suggested that some kind of environmental or genetic factors might be involved, Liu told HealthDay.

It's not clear, however, how a mother's depression might contribute to a child's asthma risk. The link might be explained partly by biology, with something happening during pregnancy; by involving environmental or genetic factors; or all three, Liu said. The study authors adjusted their findings to account for mothers' smoking during pregnancy, but they did not account for fathers' smoking or other sources of secondhand smoke.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths